Healthcare - Biotechnology - NASDAQ - US
$ 59.69
-0.0837 %
$ 2.33 B
Market Cap
-26.53
P/E
CASH FLOW STATEMENT
-50.9 M
OPERATING CASH FLOW
24.2 M
INVESTING CASH FLOW
30.2 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Longboard Pharmaceuticals, Inc.
| Net Income | -54.4 M |
| Depreciation & Amortization | 5 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 3.25 M |
| Change in Working Capital | 1.27 M |
| Others | 603 K |
| Free Cash Flow | -50.9 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|
| OPERATING CASH FLOW | ||||
| Net Income | (54.4) | (43.9) | (27.8) | (14.4) |
| Depreciation & Amortization | 5 K | 5 K | 1 K | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 3.3 | 2.7 | 2.0 | 8.5 |
| Other Operating Activities | (1.0) | 0.1 | 0.2 | 7.3 |
| Change in Working Capital | 1.3 | 3.1 | 1.0 | 2.5 |
| Cash From Operations | (50.9) | (38.1) | (24.7) | (3.4) |
| INVESTING CASH FLOW | ||||
| Capital Expenditures | 0 | 0 | 16 K | 0 |
| Other Items | 24.2 | (17.1) | (40.7) | 0 |
| Cash From Investing Activities | 24.2 | (17.1) | (40.7) | 0 |
| FINANCING CASH FLOW | ||||
| Common Stock Repurchased | 0 | 0 | 0 | (0.2) |
| Total Debt Repaid | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.6) | (0.4) | (8.3) | 58.8 |
| Cash From Financing Activities | 30.2 | (0.4) | 76.5 | 58.8 |
| CHANGE IN CASH | ||||
| Net Change In Cash | 3.6 | (55.6) | 11.0 | 55.3 |
| FREE CASH FLOW | ||||
| Free Cash Flow | (50.9) | (38.1) | (24.7) | (3.4) |